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Introduction: Poor prognosis patients with bulky stage III locally 
advanced non–small-cell lung cancer may not be offered concurrent 
chemoradiotherapy (CRT). Following a phase III trial concerning the 
effect of palliative CRT in inoperable poor prognosis patients, this 
analysis was performed to explore how tumor size influenced sur-
vival and health-related quality of life (HRQOL).
Methods: A total of 188 poor prognosis patients recruited in a ran-
domized clinical trial received four courses intravenous carbopla-
tin day 1 and oral vinorelbine day 1 and 8, at 3-week intervals. The 
experimental arm (N = 94) received radiotherapy with fractionation 
42 Gy/15, starting at the second chemotherapy course. This subset 
study compares outcomes in patients with tumors larger than 7 cm 
(N = 108) versus tumors 7 cm or smaller (N = 76).
Results: Among those with tumors larger than 7 cm, the median 
overall survival in the chemotherapy versus CRT arm was 9.7 and 
13.4 months, respectively (p = 0.001). The 1-year survival was 33% 
and 56%, respectively (p = 0.01). Except for a temporary decline 
during treatment, HRQOL was maintained in the CRT arm, regard-
less of tumor size. Among those who did not receive CRT, patients 
with tumors larger than 7 cm experienced a gradual decline in the 
HRQOL. The CRT group had significantly more esophagitis and hos-
pitalizations because of side effects regardless of tumor size.
Conclusion: In patients with poor prognosis and inoperable locally 
advanced non–small-cell lung cancer, large tumor size should not 
be considered a negative predictive factor. Except for performance 
status 2, patients with tumors larger than 7 cm apparently benefit 
from CRT.
Key Word: Non–small-cell lung cancer, Locally advanced, Bulky 
tumors, Chemoradiotherapy.
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Approximately 2800 Norwegians are diagnosed with lung cancer each year.1 In a study of all lung cancer patients 
diagnosed in southern Norway between 2002 and 2005, Rolke 
et al.2 found that 72% of patients were in an advanced, non-
operable stage at the time of diagnosis. Twenty years ago, 
palliative radiotherapy was considered the main treatment 
for advanced non–small-cell lung cancer (NSCLC), yield-
ing effective symptom relief for a limited time, regardless of 
dose/fractionation.3 Presently, the Norwegian national guide-
lines recommend combined radiotherapy and chemotherapy 
for patients with locally advanced stage III disease and good 
prognostic factors.
Large tumor volumes have been associated with a 
decreased overall survival (OS),4,5 especially when combined 
with N3 disease.6 After the development of three-dimen-
sional radiation planning and therapy, researchers have found 
that large gross tumor volume as determined by computed 
tomography (CT) and three dimensional-chemoradiotherapy 
(CRT) to be a negative prognostic factor.7–9 On behalf of 
The International Association for the Study of Lung Cancer 
(IASLC) Staging Committee and Participating Institutions, 
Ball et al.10 recently reported data from approximately 900 
NSCLC patients selected for radical radiotherapy or CRT. 
They did not observe any negative prognostic effect of tumor 
size larger than 3 cm.
Based on a comparison with treatment effect on smaller 
tumors, some authors have cautioned against the routine use 
of concurrent CRT to patients with larger volume tumors.3,11 
Several trials have excluded patients with large tumors from 
combined modality treatment.4,5,12–14 However, a poor progno-
sis does not preclude possible positive treatment effect, and 
the role of CRT for patients with NSCLC stage III nonresect-
able large volume tumors remains unresolved.
We have recently reported the results of a phase III 
trial comparing palliative concurrent CRT with palliative 
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chemotherapy alone in patients with poor prognosis nonre-
sectable locally advanced NSCLC (Conrad study).15 Because 
the majority of included patients (54%) had tumors 8 cm or 
larger in diameter, a subgroup analysis according to tumor 
size seemed feasible and warranted.
The aim of this subgroup analysis was to explore how 
tumor size influenced treatment outcomes in nonresectable 
NSCLC stage III poor prognosis patients receiving palliative 
CRT or chemotherapy alone. Investigated outcomes were OS; 
time to progression (TTP), toxicity, and health-related quality 
of life (HRQOL).
PATIENTS AND METHODS
Patients
This subset analysis is based on the Conrad study, which 
was designed to compare palliative CRT versus palliative che-
motherapy alone to poor-prognosis patients with unresectable 
locally advanced NSCLC stage III.15 The primary endpoint 
was OS, and the secondary endpoints were HRQOL, TTP, and 
toxicity. The patients were stratified by age and performance 
status (PS).
Included patients were to have unresectable, locally 
advanced NSCLC stage III disease with one or more negative 
prognostic factors (tumor size ≥8 cm, PS ≥2, and/or weight 
loss of >10% during the past 6 months). There was no upper 
age limit. The patients were staged by CT examination alone 
because positron emission tomography was not universally 
available in the years of inclusion. The patients should not 
have malignant pleural effusion, other active malignant dis-
ease, should not have received previous chemotherapy, or 
be candidates for radical radiotherapy. Patients were eligible 
provided they had World Health Organization PS16 0 to 2 and 
adequate hematological, liver, and kidney function.
Eligible patients were to receive four courses of chemo-
therapy in 3-week intervals: intravenous carboplatin (Calvert 
area under the curve 5) day 1 and oral vinorelbin 60 mg/m2 
days 1 and 8.17 The experimental arm received in addition 
radiation with 42 Gy/15 fractions during 3 weeks between 
chemotherapy course two and three. If patients in the chemo-
therapy group later (after the study treatment was completed) 
required palliative thoracic radiation, they were administered 
hypofractionated RT (17 Gy/two fractions).
From November 2006 to November 2011, 191 eligible 
patients were included from 25 hospitals in Norway. The 
Regional Ethics Committee of North Norway approved the 
study.
HRQOL
European Organization for Research and Treatment of 
Cancer (EORTC) Quality of Life Questionnaire (QLQ-C30) 
questionnaire version 3.0 and the supplementary questionnaire 
module LC13 were used to assess HRQOL. The patients were 
to complete questionnaires at each chemotherapy course, as 
well as every 8th week after termination of treatment. Among 
domains covered by the QLQ-C30/LC13, we have chosen to 
focus on mean change from baseline to 52 weeks for global 
function, social function, physical functions, and dysphagia, 
comparing the two groups of different tumor size.18 The com-
plete numbers of figures are found in a supplemental file.
Tumor Size Assessment
The largest tumor diameter (centimeter) was registered 
at randomization, according to the baseline CT examination. 
In the original Conrad protocol, tumor size 8 cm or larger 
was considered a negative prognostic factor. For inclusion, 
patients were to have tumors that could be included in a prag-
matic radiation field.
Analyses and Statistical Considerations
To stay in accordance with the IASLC tumor, node, metas-
tasis (TNM) classification, we chose tumor size 7 cm as cutoff 
for the present analysis.19 The Common Terminology Criteria of 
Adverse Events version 3.0 was used to grade toxicity.
Baseline characteristics were compared using chi-
squared tests and Fisher’s exact test. PS and possible progres-
sion were registered during follow-up visits (weeks 12, 20, 
28, 36, 44, and 52). Progressions were based on CT exami-
nation. Biopsies were not performed. OS and TTP were ana-
lyzed using the Kaplan–Meier method and compared using 
the long-rank test. Cox’s proportional hazard model was used 
for multivariate analysis to estimate the independent impact of 
clinical factors on survival.
The EORTC scoring manuals were used to analyze the 
HRQOL questionnaires.20,21 Mean scores were calculated from 
the reported scores only. The mean changes were calculated by 
subtracting baseline score from the score at each designated time 
point during and after the treatment. The scores were compared 
using analysis of variance (ANOVA) and the nonparametric 
Mann–Whitney U test. A mean change of 10 points or greater 
was considered clinically relevant.22,23 A higher score for symp-
tom domains indicates more pronounced symptoms, whereas 
higher score for the functional domains indicates better function.
RESULTS
Patients and Study Treatment
The demographic data for subgroup comparisons are 
shown in Table 1. Of the 188 eligible patients in the Conrad 
study, four were excluded because of missing information on 
tumor diameter. Seventy-eight patients had tumors 7 cm or 
smaller, and 108 patients had tumors larger than 7 cm. There 
were no significant differences between the groups with respect 
to demographic or clinical variables. There was a tendency 
toward more CRT (55% versus 43%) and more PS 2 patients 
(25% versus 17%) in the larger than 7 cm group when com-
pared with the 7 cm or smaller group. Among patients receiv-
ing CRT, there was a relative predominance of women in the 
group with tumors larger than 7 cm compared with the group 
with tumors 7 cm or smaller (39% versus 30%, respectively). 
In the same group, we found a relative deficit of patients with 
weight loss larger than 10% (34% versus 55%, respectively).
Treatment Received
Treatment according to group is shown in Table 2. In 
the 7 cm or smaller group, the mean number of chemotherapy 
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cycles was 3.5 and 3.7 (chemo versus CRT) versus 3.6 and 3.6 
(chemo versus CRT) in the larger than 7 cm group.
Among patients with tumors larger than 7 cm random-
ized to CRT, three patients did not receive radiotherapy: One 
patient because of death from complications after a femoral 
neck fracture (n = 1) and two patients because of significantly 
reduced PS after initial chemotherapy (n = 1) and myocar-
dial infarction (n = 1). One patient died of arrhythmia during 
radiation treatment. Less than 10% of patients with tumors 
larger than 7 cm randomized to CRT discontinued treatment 
because of disease progression or unacceptable toxicity. The 
mean number of fractions was 13.6 of the planned 15 in this 
group. In the group of smaller tumors, all patients randomized 
to CRT completed radiotherapy.
Local Control and Poststudy Treatment
Data on lung progression/recurrence and poststudy 
treatment are presented in Table 3. CRT yielded a significantly 
better local control when compared with chemotherapy alone 
in the tumor larger than 7 cm group (p = 0.01). In 69% and 
68% of patients receiving chemotherapy alone, the lungs 
were reported to be the first site of recurrence/progression. 
In comparison, this was seen in only 41% to 45% of patients 
treated with CRT. Consistently, the need for additional therapy 
seemed to be more pronounced among those treated with che-
motherapy alone, irrespective of tumor size.
Although the information on the use of erlotinib is 
incomplete, it seems to be more pronounced for patients with 
tumors larger than 7 cm.
Outcomes
This subgroup analysis showed that the improved sur-
vival seen after CRT when compared with chemotherapy 
alone was primarily mediated by the group of patients with 
tumors larger than 7 cm (Fig. 1). Although the 2-year OS in 
TABLE 1.  Baseline Characteristics
Mean Age
Tumor ≤7 cm
(n = 76)
Tumor >7 cm
(n = 108)
p Valuea
Chemo CRT
p Value
Chemo CRT
p Value
67 68 68 67
No. of 
Patients %
No. of 
Patients %
No. of 
Patients %
No. of 
Patients %
Sex NS NS NS
  Female 19 44 10 30 15 31 23 39
  Male 24 56 23 70 34 69 36 61
Performance status NS NS NS
  0–1 34 79 29 88 39 80 42 71
  2 9 21 4 12 10 20 17 29
Weight loss NS NS NS
  <10% 28 65 15 45 33 67 39 66
  ≥10% 15 35 18 55 16 33 20 34
T NS NS NS
  0 or 1 or 2 13 30 11 33 9 18 11 19
  T3 15 35 7 21 15 31 17 29
  T4 15 35 15 46 25 51 31 52
N NS NS NS
  0 or 1 13 30 7 21 11 22 8 14
  2 20 47 16 49 18 37 32 54
  3 10 23 10 30 20 41 19 32
Stage NS NS NS
  IIIA 25 58 14 42 20 41 26 44
  IIIB 18 42 19 58 29 59 33 56
Histology NSb NSb NSb
  Squamous cell 
carcinoma
17 40 16 49 17 35 30 51
  Adenocarcinoma 14 33 11 33 17 35 18 30
  Large cell carcinoma 1 1.0 1 3.0 3 6.1 0 0
  Others 11 26 5 15 12 25 11 19
Values are expressed as numbers and %.
aExact two-sided p value for testing null hypothesis of no difference in parameter’s distribution between patients with small and large tumors receiving CRT.
b Fisher’s exact test for testing null hypothesis of no difference in parameter’s distribution between the two groups of patients receiving radiation as part of the study therapy.
NS, not significant; chemo, chemotherapy; CRT, chemoradiotherapy.
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patients with tumors 7 cm or smaller increased from 9.3% 
to 24% (p = 0.11) with the addition of concurrent radio-
therapy, an increase from 6.1% to 32% (p = 0.001) was 
observed among those with tumors larger than 7 cm (Fig. 1). 
Consistently, median TTP seemed, regardless of tumor size, 
significantly longer after CRT (≤7 cm: 6.7 versus 4.5 months, 
p < 0.05; >7 cm: 7.2 versus 4.2 months, p < 0.001).
In a multivariate analysis adjusting for weight loss, PS, 
and sex, only PS and tumor size were found to have signif-
icant impact on survival: hazard ratio = 1.835 for PS 0 to 
1 versus 2 (confidence interval, 1.26–2.67; p = 0.002) and 
hazard ratio = 0.937 (0.881–0.996, p = 0.037), respectively. 
Tumor size was not dichotomized in this analysis so that no 
information is lost.
Toxicity and side effects are summarized in Table 4. 
Except for anemia in the tumor 7 cm or smaller group, there 
were no significant differences in hematological toxicity 
related to tumor size. The number of patients with esophagitis 
and hospital admissions attributable to side effects was higher 
in both groups receiving CRT.
Of 184 eligible patients, 182 (99%) completed the 
HRQOL questionnaire at randomization. The median 
TABLE 2.  Treatment According to Tumor Size
Characteristics
Tumor ≤7 cm Tumor >7 cm
Chemo (N = 43) CRT (N = 33) p Value Chemo (N = 49) CRT (N = 59) p Value
Number chemotherapy courses (184 valid) NS NS
  0 0 0 0 1 (1.7)
  1 4 (9.3) 0 0 1 (1.7)
  2 2 (4.7) 3 (9.1) 6 (12) 8 (14)
  3 4 (9.3) 4 (12) 7 (14) 3 (5.1)
  4 33 (77) 26 (79) 36 (74) 46 (78)
  Mean 3.5 3.7 3.6 3.6
Discontinued because of NS NS
  Disease progression 5 2 9 2
  Unacceptable toxicity 1 2 2 5
  Intercurrent disease 1 1 0 1
  Patient wish 0 0 1 0
  Other reasons 3 2 1 5
No RT fractions (92 valid)
  0 0 3 (5.1)
  1 0 1 (1.7)
  2 0 0
  3–14 0 5 (8.5)
  15 33 (100) 50 (85)
RT discontinued because of
  Disease progression 0 3 0.024a
  Unacceptable toxicity 0 2
  Intercurrent disease 0 0
  Other reasons 0 4
Values are expressed as numbers (%).
a Fisher’s exact test for testing null hypothesis of no difference in parameter’s distribution between the two groups of patients receiving radiation as part of the study therapy.
Chemo, chemotherapy; CRT, chemoradiotherapy; RT, radiation treatment; NS, not significant.
TABLE 3.  Lung Recurrence and Poststudy Treatment
Characteristics
Tumor ≤7 cm Tumor >7 cm
Chemo (N = 43) CRT (N = 33) p Valuea Chemo (N = 49) CRT (N = 59) p Valuea
Initial recurrence in lungs (176 valid) 29 (69) 14 (45) 0.05 32 (68) 23 (41) 0.01
Radiotherapy (175 valid) 18 (44) 1 (3.2) <0.001 26 (55) 2 (3.6) <0.001
Chemotherapy (161 valid) 17 (42) 7 (26) NS 17 (39) 14 (29) NS
Received erlotinib (159 valid) 4 (11) 1 (3.7) NS 9 (20) 12 (23) NS
Values are expressed as numbers (%).
aFisher’s exact test (two-sided).
Chemo, chemotherapy; CRT, chemoradiotherapy; NS, not significant.
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percentage of completed questionnaires during the first 6 
months after randomization was 91% in the 7 cm or smaller 
group and 86% in the larger than 7 cm group. The percent-
age of responders declined the past 6 months of the observa-
tion period (median, 72% versus 73%). Regardless of tumor 
size, patients receiving CRT recorded a temporal worsening 
in physical and social functioning before returning to base-
line levels again. All groups experienced a certain decline in 
physical and social functions at the end of the observational 
period, but the decline was significantly more pronounced 
among the patients with tumors larger than 7 cm who did not 
receive CRT.
DISCUSSION
This subset analysis of a randomized phase III trial dem-
onstrates that patients with large locally advanced NSLCL 
FIGURE 1.  Kaplan–Meier plots for (A) TTP for patients with tumors 7 cm or smaller; (B) TTP for patients with tumors larger 
than 7 cm; (C) overall survival for patients with tumors 7 cm or smaller; (D) overall survival for tumors larger than 7 cm; (E) 1- 
and 2-year survival in both groups. CI, confidence interval; TTP, time to progression.
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stage III tumors and negative prognostic factors may possibly 
be better served by concurrent CRT than by chemotherapy 
alone, with patients with PS 2 being the exception.
The preferred treatment for locally advanced (LA)-
NSCLC is concurrent chemoradiation with high-dose chemo-
therapy.24 However, some authors question the benefit of CRT 
to patients with LA-NSCLC and large tumors.3,11 The aim of the 
Conrad trial was to study how poor prognosis NSCLC stage III 
patients responded to a palliative combination regimen of radia-
tion and chemotherapy. Because we considered PS 2; weight 
loss larger than 10% and tumor size 8 cm or larger to be nega-
tive prognostic factors, the high percentage of patients with large 
tumors in this material is caused by the aim of the original study.
The original phase III trial (the Conrad study), on which 
this substudy is based, confirmed a significant benefit from 
palliative CRT compared with palliative chemotherapy alone, 
with a median survival of 12.6 months versus 9.7 months, 
respectively.15 Palliative CRT increased OS time regardless 
of tumor size, and the survival gain was most prominent for 
patients with tumors larger than 7 cm (1-year survival 56% 
versus 33%; 2-year survival 32% versus 6.1%). The median 
survival time for patients with tumors larger than 7 cm was 
comparable with the findings in other studies,5,7 where better 
prognosis patients received definitive CRT or radiation alone. 
In a smaller retrospective material, Wiersma et al.6 found that 
approximately one of five patients with large tumors survived 
3 years when given treatment with definitive CRT containing 
a cisplatin doublet. In our material, we observed a slightly bet-
ter 3-year survival (20%) in the larger than 7 cm tumor group 
receiving palliative CRT.
Several authors have reported a strong sex-dependent 
difference in survival among patients with NSCLC.25–27 Weight 
loss at time of diagnosis is also a factor known to have impact 
on survival.28–30 Sex and weight loss were not significant pre-
dictive factors in our study. However, there were somewhat 
less weight loss and more women in the tumor larger than 
7 cm group, and especially for those treated with CRT. This 
may possibly have contributed to the increased survival in the 
group of tumors larger than 7 cm. In contrast, poor PS 2, being 
one of the strongest prognostic factors in NSCLC,30 was over-
represented in the tumor larger than 7 cm group and especially 
for the CRT treated.
TABLE 4.  Toxicity According to Tumor Size and Treatment
Characteristics
Tumor ≤7 cm Tumor >7 cm
Chemo CRT p Valuea Chemo CRT p.Valuea p Valueb
Hematological toxicities (181 valid)
  Anemia 0.003 NS NS
   Grade 3 3 (7.3) 1 (3.0) 2 (4.1) 4 (6.9)
   Grade 4 0 0 0 0
  Neutropenia NS NS NS
   Grade 3 7 (17) 8 (24) 13 (27) 10 (17)
   Grade 4 5 (12) 6 (18) 9 (18) 17 (29)
  Thrombocytopenia NS NS NS
   Grade 3 3 (7.3) 3 (9.1) 0 3 (5.2)
   Grade 4 0 0 1 (2.0) 3 (5.2)
No. of infections in relation to 
leucopenia (167 valid)
NS NS NS
  1 3 (7.9) 6 (22) 13 (28) 15 (27)
  2 1 (2.6) 2 (7.4) 0 2 (3.6)
  3 1 (2.6) 0 0 0
No. of hospital admissions in 
relation to side effects (167 
valid)
0.048 0.07 NS
  1 6 (16) 9 (32) 12 (26) 23 (42)
  2 1 (2.6) 4 (14) 2 (4.3) 5 (9.1)
  3 1 (2.6) 1 (3.6) 0 2 (3.6)
Esophagitis in relation to 
radiation (156 valid)
27 valid cases 33 valid cases <0.001 39 valid cases 56 valid cases <0.001 NS
  Grade 0 24 (89) 6 (18) 33 (85) 6 (11)
  Grade 1 2 (7.4) 4 (12) 2 (5.1) 12 (21)
  Grade 2 1 (3.7) 13 (39) 3 (7.7) 22 (39)
  Grade 3 0 10 (30) 1 (2.6) 16 (29)
Values are expressed as numbers (%).
aFisher’s two-sided p value for testing null hypothesis of no difference in parameter’s distribution between patients receiving chemotherapy or CRT.
bFisher’s two-sided p value for testing null hypothesis of no difference in parameter’s distribution between patients with small and large tumors receiving CRT.
Chemo, chemotherapy; CRT, chemoradiotherapy; NS, not significant.
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The CRT patients experienced a significantly increased 
incidence of esophagitis and had significantly more hospi-
talizations attributable to side effects regardless of tumor 
size. Beyond this, the hematological toxicities were modest, 
and no serious pulmonary toxicity was observed. This may 
be explained by chemotherapy doses and radiation being 
adjusted to a palliative intent. Besides, the relatively large per-
centage of CRT patients who developed esophagitis may be 
diminished by modern radiation techniques in the future.31,32
A large tumor is expected to give more symptoms than 
a smaller one. CRT may relieve these symptoms. However, 
radiation and chemotherapy are related to certain side effects 
that will influence symptoms and quality of life during and 
shortly after the treatment period.33,34 In this study, profiles of 
the HRQOL recordings demonstrate an increase in dyspha-
gia and a decline in functional values during treatment. As 
expected, this was most pronounced for those receiving CRT. 
However, the post-treatment beneficial HRQOL changes for 
those treated with CRT were most evident for patients with 
larger tumors (>7 cm).
The lack of available positron emission tomography-CT 
scanning in Norway at the time of inclusion may imply that 
the study group does not reflect the current stage III NSCLC 
population. By using CT alone, one may underestimate nodal 
involvement and/or overestimate tumor size by unintention-
ally including atelectasis. Considering that approximately 
80% of our patients had N3 disease, this will not weaken the 
argument for CRT to patients with tumors larger than 7 cm.
Several authors have found the TNM classification 
system inaccurate or insufficient in predicting the treat-
ment effect on survival in nonoperable NSCLC patients, 
especially with respect to the impact of tumor size.5,35,36 An 
unfortunate lack of distinction between predictive and prog-
nostic factors may be one reason.37 It should be noted that a 
prognostic factor provides information on the likely outcome 
of a cancer disease in an untreated individual, whereas a 
predictive factor provides information about the likely effect 
of a treatment.38
Morgensztern et al.,4 who examined 12,315 patients 
with locally advanced stage III NSCLC N2-3 disease from 
the Surveillance, Epidemiology and End Results (SEER) reg-
istry, included patients strictly on the basis of TNM staging, 
regardless of the treatment. They found tumor size to be an 
independent prognostic factor. Ball et al. recently published 
the results data on 868 patients of all TNM stages included 
in The IASLC Staging Project. The tumor diameters were 
known, and the cancers were subjected to radical radiotherapy 
or combined chemotherapy and radiotherapy.10 The authors 
found that tumor size smaller than 3 cm was associated with a 
longer survival than larger tumors, but evidence on the prog-
nostic effect by increasing size above the 3-cm cutoff was 
weak. The assessments have been made on comparisons with 
treatment effect on smaller tumors. Accordingly, they do not 
tell us much about how treatment on larger tumors compares 
with no treatment or best supportive care.
Werner-Wasik et al.39 specifically addressed treatment 
effect on different tumor volumes in a small study published 
in 2008. They found that larger tumor volumes were associ-
ated with larger risk of local failure, and smaller tumors were 
associated with improved OS. But these findings were not 
compared with a control group. Several other authors have 
addressed tumor size and volume as a prognostic factor for 
survival.5,7,9,36 All these studies have dealt with patients who 
received definitive treatment. But while these authors, to a 
varying degree, demonstrate that a large tumor may be a nega-
tive prognostic factor, the treatment effect was not specifically 
addressed. A poor prognosis does not preclude an excellent 
treatment effect. These studies cannot be used as an argument 
against treating bulky tumors.
Aupérin et al.40 found that CRT has a significant effect 
on locoregional control. This is consistent with the findings in 
our study: Regardless of tumor size, patients receiving CRT 
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had a significant reduction in lung recurrence and progression. 
However, the percentages of recurrence and progression in the 
lungs after CRT in our study (approximately 40%) were con-
siderably larger than those in the limited material of Alexander 
et al.5 (11%). This may reflect that the radiation dose in our 
study was too low.41 Further research should be performed on 
bulky NSCLC tumors, employing modern, more advanced, 
radiation techniques.
To our knowledge this is the first study to explore the 
effect of CRT compared with chemotherapy alone in poor-
risk NSCLC patients with bulky tumor masses. Our results 
demonstrate that, although a large tumor may be considered a 
negative prognostic factor, it is not a negative predictive fac-
tor. Patients with large NSCLC tumors seem to benefit notably 
from concomitant chemoradiation.
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